Teyi Pharmaceutical Group Co.,Ltd (SHE:002728)
China flag China · Delayed Price · Currency is CNY
11.08
-0.17 (-1.51%)
Apr 9, 2026, 3:04 PM CST

SHE:002728 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Operating Revenue
923.81686.911,066886.15757.93
Other Revenue
0.720.880.740.430.23
924.53687.791,067886.57758.16
Revenue Growth (YoY)
34.42%-35.55%20.38%16.94%19.83%
Cost of Revenue
421.17386.47467.98451.83356.12
Gross Profit
503.36301.32599.23434.74402.04
Selling, General & Admin
371.5225.54240.67176.38175.95
Research & Development
44.4143.3343.0638.0137.78
Other Operating Expenses
7.912.059.381.759.27
Operating Expenses
422.54270.89293.19216.74224.72
Operating Income
80.8230.43306.04217.99177.33
Interest Expense
-4.23-5.32-16.36-29.13-29.51
Interest & Investment Income
3.5710.3412.348.5512.14
Other Non Operating Income (Expenses)
0.37-0.45-0.4-1.44-0.42
EBT Excluding Unusual Items
80.5334.99301.61195.97159.53
Impairment of Goodwill
--11.63-13.17--23.06
Gain (Loss) on Sale of Assets
-0.070.010.120.040.1
Asset Writedown
-0.82-0.16-0.27-0.12-0.37
Other Unusual Items
2.64-1.164.70.4310.91
Pretax Income
82.2822.05292.99196.32147.1
Income Tax Expense
0.611.5639.8218.1220.18
Net Income
81.6720.5253.18178.2126.92
Net Income to Common
81.6720.5253.18178.2126.92
Net Income Growth
298.50%-91.91%42.07%40.41%189.66%
Shares Outstanding (Basic)
510512460438401
Shares Outstanding (Diluted)
510512460438401
Shares Change (YoY)
-0.38%11.31%5.16%9.09%2.75%
EPS (Basic)
0.160.040.550.410.32
EPS (Diluted)
0.160.040.550.410.32
EPS Growth
300.00%-92.73%35.10%28.71%181.91%
Free Cash Flow
164.54-136.11112.51281.39147.24
Free Cash Flow Per Share
0.32-0.270.240.640.37
Dividend Per Share
0.1500.0500.3570.3320.332
Dividend Growth
200.00%-86.00%7.69%--
Gross Margin
54.45%43.81%56.15%49.04%53.03%
Operating Margin
8.74%4.42%28.68%24.59%23.39%
Profit Margin
8.83%2.98%23.72%20.10%16.74%
Free Cash Flow Margin
17.80%-19.79%10.54%31.74%19.42%
EBITDA
150.6494.79366.14270.52228.63
EBITDA Margin
16.29%13.78%34.31%30.51%30.16%
D&A For EBITDA
69.8264.3760.152.5251.31
EBIT
80.8230.43306.04217.99177.33
EBIT Margin
8.74%4.42%28.68%24.59%23.39%
Effective Tax Rate
0.74%7.06%13.59%9.23%13.72%
Revenue as Reported
924.53687.791,067886.57758.16
Source: S&P Global Market Intelligence. Standard template. Financial Sources.